Table 1 Dose escalation schedule, number of patients treated, and DLTs
From: Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
Dose level | Nab-paclitaxel dose, mg/m2, days 1, 8, 15 | Bevacizumab dose, mg/kg, days 1, 15 | Gemcitabine dose, mg/m2, days 1, 8, 15 | Number of patients treated | Number of patients with DLTsa |
|---|---|---|---|---|---|
1 | 50 | 5 | 1000 | 3 | 0 |
2 | 75 | 5 | 1000 | 6 | 0 |
3 | 50 | 10 | 1000 | 6 | 1 (thrombocytopenia, dehydration, dysphagia, and dyspnea) |
4 | 100 | 5 | 1000 | 17 | 2 (1 diarrhoea; 1 fatigue)b |
5 | 75 | 10 | 1000 | 16 | 1 (cellulitis); 2 (GI bleeding)b |
6 | 50 | 15 | 1000 | 6 | 0 |
7 | 125 | 5 | 1000 | 7 | 0 |
8 | 100 | 10 | 1000 | 6 | 0 |
9 | 75 | 15 | 1000 | 18 | 0 |
10 | 150 | 5 | 1000 | 6 | 1 (bacteremia, fatigue, and dehydration) |
11 | 125 | 10 | 1000 | 3 | 0 |
12 | 100 | 15 | 1000 | 3 | 0 |
13 | 150 | 10 | 1000 | 3 | 0 |
14 | 125 | 15 | 1000 | 3 | 0 |
15 | 150 | 15 | 1000 | 3 | 0 |
